➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Dow
McKinsey
Moodys
Express Scripts

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,278,923

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,278,923
Title:Oral dosing of GLP-1 compounds
Abstract: The present invention relates to improved uses of GLP-1 peptides in oral therapy.
Inventor(s): Nielsen; Flemming S. (Roskilde, DK), Sauerberg; Per (Farum, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:15/651,043
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 10,278,923

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo RYBELSUS semaglutide TABLET;ORAL 213051-001 Sep 20, 2019 RX Yes No   Start Trial   Start Trial METHOD OF TREATING TYPE 2 DIABETES MELLITUS   Start Trial
Novo RYBELSUS semaglutide TABLET;ORAL 213051-002 Sep 20, 2019 RX Yes No   Start Trial   Start Trial METHOD OF TREATING TYPE 2 DIABETES MELLITUS   Start Trial
Novo RYBELSUS semaglutide TABLET;ORAL 213051-003 Sep 20, 2019 RX Yes Yes   Start Trial   Start Trial METHOD OF TREATING TYPE 2 DIABETES MELLITUS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,278,923

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
13166205May 2, 2013

International Family Members for US Patent 10,278,923

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014261336   Start Trial
Brazil 112015026325   Start Trial
Canada 2910903   Start Trial
Cyprus 1120730   Start Trial
Denmark 2991671   Start Trial
European Patent Office 2991671   Start Trial
European Patent Office 3485900   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Medtronic
Colorcon
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.